Clinical trial
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in…
NCT00454168 · The Vaccine Company, Industry · Unknown status
Key facts
| NCT number | NCT00454168 |
|---|---|
| Title | Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission |
| Official title | A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study |
| Lead sponsor | The Vaccine Company, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Other |
| Interventions | PR1 leukemia peptide vaccine, sargramostim, placebo |
| Enrollment | 244 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2009 |
| First posted | Mar 30, 2007 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: